Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iMMagine-1: Anitocabtagene-autoleucel for Relapsed/Refractory Multiple Myeloma
NCT05396885Phase 2Active, not recruiting
- Sponsor
- Kite Pharma
- Start
- Jul 2022
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 2 trial of anitocabtagene autoleucel in multiple myeloma (MM), sponsored by Kite Pharma. Started Jul 2022; status: active, not recruiting.
02
Drugs
anitocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05396885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05396885.